JAK2V617F mutation and circulating extracellular vesicles in
essential thrombocythemia

J 2023

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ, Miroslav PENKA et. al.

Základní údaje

Originální název

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia

Autoři

ASWAD, Mohamed Hussam (760 Sýrie, garant, domácí), Jarmila KISSOVÁ (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika, domácí), Lucie ŘÍHOVÁ (203 Česká republika, domácí) a Miroslav PENKA (203 Česká republika, domácí)

Vydání

CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, AMSTERDAM, IOS PRESS, 2023, 1386-0291

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.100 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130986

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3233/CH-221678

UT WoS

001076811500002

Klíčová slova anglicky

Essential thrombocythemia; thrombosis; risk factor; JAK2V617F mutation; extracellular vesicles

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2024 14:05, Mgr. Tereza Miškechová

Anotace

V originále

The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients’ mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2V617F-positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7–83.7], P = 0.013), and that JAK2V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47–8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2V617F mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.

Citovat

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ a Miroslav PENKA. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia. CLINICAL HEMORHEOLOGY AND MICROCIRCULATION. AMSTERDAM: IOS PRESS, 2023, roč. 84, č. 4, s. 359-368. ISSN 1386-0291. Dostupné z: https://dx.doi.org/10.3233/CH-221678.

@article{2291837,
   author = {Aswad, Mohamed Hussam and Kissová, Jarmila and Ovesná, Petra and Říhová, Lucie and Penka, Miroslav},
   article_location = {AMSTERDAM},
   article_number = {4},
   doi = {http://dx.doi.org/10.3233/CH-221678},
   keywords = {Essential thrombocythemia; thrombosis; risk factor; JAK2V617F mutation; extracellular vesicles},
   language = {eng},
   issn = {1386-0291},
   journal = {CLINICAL HEMORHEOLOGY AND MICROCIRCULATION},
   title = {JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia},
   url = {https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch221678},
   volume = {84},
   year = {2023}
}

TY  - JOUR
ID  - 2291837
AU  - Aswad, Mohamed Hussam - Kissová, Jarmila - Ovesná, Petra - Říhová, Lucie - Penka, Miroslav
PY  - 2023
TI  - JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia
JF  - CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
VL  - 84
IS  - 4
SP  - 359-368
EP  - 359-368
PB  - IOS PRESS
SN  - 13860291
KW  - Essential thrombocythemia
KW  - thrombosis
KW  - risk factor
KW  - JAK2V617F mutation
KW  - extracellular vesicles
UR  - https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch221678
N2  - The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients’ mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2V617F mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2V617F-positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7–83.7], P = 0.013), and that JAK2V617F mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47–8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2V617F mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2V617F mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.
ER  -

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ a Miroslav PENKA. JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia. \textit{CLINICAL HEMORHEOLOGY AND MICROCIRCULATION}. AMSTERDAM: IOS PRESS, 2023, roč.~84, č.~4, s.~359-368. ISSN~1386-0291. Dostupné z: https://dx.doi.org/10.3233/CH-221678.

Podrobný výpis o publikaci